Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Pre-Seed and Seed Stage VC Firm Backing AI and Next-Generation Computing in Healthcare

18 Feb

A pre-Seed and Seed-stage venture capital firm is focused on AI and next-generation computing technologies applied to large industries. The firm prefers to invest in companies located in North America.  

The firm partners with entrepreneurs addressing real-world problems through data and machine learning, with a focus on frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Prior investment areas have included biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, automated pathology solutions, and related technologies. 

From a company and management team perspective, the firm seeks experienced teams with a strong long-term vision. The firm may take a board seat when the firm brings specific domain expertise relevant to the company. The firm does not have a fixed equity ownership target. The firm values strong technical teams with deep market understanding and is comfortable partnering with very early-stage companies, including those at the pre-product stage. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Seed Fund Focuses on Early-Stage Breakthrough Technologies Addressing Longevity and Healthspan

10 Feb

A venture capital firm is focused on investing in breakthrough technologies that aim to prevent disease and extend healthspan and lifespan. The firm’s investment sweet spot is at the Seed stage and the firm may consider Series A opportunities on a case-by-case basis. Typical check sizes are around $1M, with the ability to invest up to $5M. The firm is open to opportunities globally, with a particular focus on Europe and the United States. The firm generally does not lead investment rounds or take board seats but provides active support to portfolio companies.  

The firm seeks to invest in genuinely innovative and differentiated therapeutics and digital health opportunities. Within therapeutics, the firm prefers areas outside of oncology, with a focus on novel biological targets. Areas of particular interest include aging-related technologies, especially regenerative or reversal approaches rather than simple lifespan extension. Within digital health, the firm is interested in consumer-facing technologies that improve accessibility to healthcare.  

The firm is open to engaging at very early stages, including lab spinouts. The firm does not impose specific requirements on companies or management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Asia-Based VC Firm Engages in Cross Border Investments Across Life Sciences and Tech-Driven Healthcare Companies

10 Feb

The firm is a venture capital firm focused on investments across life sciences, healthcare, and advanced technology sectors. The firm invests in biopharmaceuticals, diagnostics, medical devices, digital health, functional foods, and AI-driven technologies, as well as convergent applications spanning areas such as autonomous systems, robotics, semiconductors, energy, and telecommunications. The firm manages multiple investment vehicles and continues to expand its investment activities through successive funds.  

Historically, the firm has invested primarily in domestic companies but is actively seeking new investment opportunities in the United States.  

Within life sciences and healthcare, the firm invests across biopharmaceuticals, diagnostics, medical devices, digital health, and functional foods. The firm also supports AI-enabled and cross-disciplinary technologies that bridge healthcare with advanced engineering and data-driven innovation. Within biopharmaceuticals, the firm evaluates both preclinical and clinical-stage companies developing innovative therapeutic and diagnostic solutions.  

From a company and management team perspective, the firm prioritizes businesses built on strong fundamental technologies with sustainable growth potential. The firm favors teams that demonstrate technical excellence, long-term commitment, and the ability to execute effective commercialization strategies. The firm emphasizes close partnership with founders who are resilient, innovation-driven, and oriented toward building globally competitive companies, and provides active support from early development through later-stage growth and exit. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Biotech and Healthcare Focused Incubator and Investment Firm Invests from Seed to Pre-IPO Rounds Across the Globe

10 Feb

An investment firm and incubator is focused on biotechnology and healthcare. The firm prefers to participate in early-stage and Seed financings as well as later-stage and pre-IPO rounds. The firm typically makes a limited number of investments per year, with initial allocation sizes generally ranging from $500K to $5M for early-stage opportunities and approximately $2M to $10M for later-stage investments. The firm utilizes flexible capital structures on a case-by-case basis and has experience with both equity investments and convertible loans. While the firm primarily invests in U.S.-based companies, the firm is open to evaluating opportunities globally.  

The firm is primarily interested in biotechnology therapeutics and medical technology. The firm considers a wide range of therapeutic modalities and has particular expertise in molecule development, while generally avoiding medical devices and digital health. The firm will evaluate diagnostic opportunities but prefers a focus on genomics and biomarker-based diagnostics. The firm considers therapeutics at the preclinical stage through Phase I, Phase II, and Phase III clinical development, as well as medical technology and diagnostics that are in development or clinical stages. The firm is disease-agnostic and evaluates opportunities across indications, with prior experience in oncology and autoimmune-related technologies.  

From a company and management team perspective, the firm prefers to partner with experienced management teams that are fully dedicated to their technology and company. The firm is an active investor and may take a board seat on a case-by-case basis depending on investment size. The firm is open to acting as both a lead investor and a co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

Hot Investor Mandate: Europe-Based VC Invests in Pre-Seed and Seed Stage Companies in the Intersection of Deeptech and Life Sciences

10 Feb

A venture capital firm that historically focused on deep-tech and hardware is now expanding its scope to opportunities at the intersection of deep-tech and life sciences. The firm is currently investing from its second fund, sized at approximately USD $75M. The firm participates in Pre-Seed and Seed financing rounds, with typical allocations ranging from USD $500K to $2.5M. The firm prefers to lead or co-lead investment rounds and evaluates opportunities across Europe and the United States.  

Within life sciences, the firm is open to digital health deep-tech companies but does not invest in application-only businesses. The firm does not pursue traditional therapeutics but will consider therapeutics that incorporate a strong data component, as well as multi-asset or platform-based technologies. The firm is also interested in diagnostics, non-invasive medical devices, surgical tools, and biomanufacturing. The firm focuses on companies at the pre-clinical and early development stages and is disease-agnostic.  

The firm does not impose strict requirements on companies or management teams. The firm may consider taking a board seat or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm Invests in Seed-Stage Life Science Companies in North America and Europe Addressing Age-Related Diseases

3 Feb

A venture capital platform with a dedicated life sciences fund is focused on Seed-stage investments. The fund typically invests around $1M per company and does not have a strict preference between leading rounds or co-investing. The firm is open to opportunities across North America and Europe.  

Within life sciences, the fund focuses on therapeutics, medtech, digital health, and broader biotech ecosystem companies addressing age-related diseases. Areas of interest include cardiovascular disease, cancer, respiratory illnesses, dementia, Alzheimer’s disease, diabetes, and kidney disease.  

Within therapeutics, the fund emphasizes “repair and replace” approaches, including regenerative medicine, gene therapy, and immunotherapy. In medtech, the fund is interested in wearables, biosensors, and remote patient monitoring technologies. In digital health, areas of focus include AI-driven drug discovery and solutions that optimize clinical trial execution. Within the biotech ecosystem, the fund is drawn to bioprinting, biomaterials, and drug delivery platforms.  

From a company and management team perspective, the firm seeks businesses with a strong scientific foundation, compelling and differentiated innovation, and the ability to scale. Management teams are expected to demonstrate a balanced mix of scientific expertise, business development capabilities, administrative leadership, and marketing experience. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Newly Established Corporate Venture Initiative Strategically Invests in Life Sciences and AI-Powered Healthcare Technologies

3 Feb

The firm is a newly established corporate venture capital operating platform launched as part of a large global conglomerate’s corporate strategy focused on value creation and long-term growth. The firm represents the parent organization’s first company-wide corporate venture capital initiative and is designed to make flexible investments across a broad range of sectors, particularly those with large future markets and high growth potential where the parent organization can contribute differentiated value through global networks, industry and customer access, and technology and academic partnerships.  

Through the firm, the parent organization aims to accelerate collaboration with startups, identify business opportunities beyond existing core businesses, commercialize emerging technologies, support industrial application, and enable international expansion.  

The firm primarily focuses on early-stage companies, starting at Seed stage, but is able to invest across Seed through later-stage opportunities. The firm invests across a broad set of innovation-driven sectors, including AI, software, bio and healthcare, robotics, aerospace, next-generation computing, and other advanced technology domains. The investment strategy emphasizes areas where the firm can actively support commercialization, industrial deployment, and global scaling by leveraging the parent organization’s extensive industrial ecosystem.  

From a company and management team perspective, the firm partners with startups that are aligned with a broader transformation agenda and are capable of leveraging a global industrial platform to achieve scalable growth and international reach. The firm favors founding teams with deep technical expertise, strong commercialization potential, and the ability to engage effectively with industry, academic, and corporate networks. Investments are typically structured as equity participation, with active strategic support through customer access, supply-chain capabilities, and global operational resources to accelerate growth and value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

← Older Entries
Newer Entries →